FGF23 and diabetic kidney disease: Furthermore, in db/db mice, which are an animal model of type 2 diabetes, blocking of FGF23 action by the administration of the C-terminal tail of FGF23 improved diabetic nephropathy by decreasing inflammation and fibrosis without changing the blood levels of phosphate or FGF23 [67,68].